Welireg Plus Cabometyx Shows Anti-Tumor Activity in Kidney Cancer Type
The Welireg-Cabometyx treatment combination demonstrated anti-tumor activity for some patients with clear cell renal carcinoma, according to a phase 2 trial.
Pluvicto Improves Survival Without Progression in Certain Patients With Prostate Cancer
Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.
PSMA-Targeted Therapy May Decrease PSA Levels in Metastatic Prostate Cancer Subset
Patients with metastatic castration-resistant prostate cancer treated with radioligand therapy, a form of targeted therapy, had improvements in PSA levels and survival with favorable side effect profiles.
Cabometyx Failed to Improve Survival in Advanced Bladder Cancer
While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.
Even in the Prescence of Health Complications and Other Medications, Nubeqa Maintains Safety, Efficacy in Prostate Cancer Treatment
Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.
Trimodality Treatment Including Keytruda May Provide Non-Surgical Treatment Option for Subset of Bladder Cancer
Keytruda plus gemcitabine and higher doses of radiotherapy showed promising efficacy and safety results in patients with muscle-invasive bladder cancer.
Novel Therapy Appears Safe in Certain Patients with Prostate Cancer
The treatment was also associated with antitumor activity in patients with metastatic castration-resistant prostate cancer.
